Posts in Uncategorized

Local Presence in the EU: The Roles You Must Actually Have on the Ground

Entering the European market is not one establishment decision but several. Some roles must sit inside the EEA, some inside a specific Member State, some[…]

Launch Sequencing in Europe: How One Price Shapes Thirty Markets

Almost every European country sets medicine prices partly by looking at what other European countries pay. That single fact turns a sequence of national pricing[…]

Greece as a European Entry Point: What Launching Here Actually Involves

Greece is a full EU Member State with a mature regulatory authority, high pharmaceutical consumption and a price that travels well beyond its borders. It[…]

Pharmacovigilance Inspection Readiness: What the Published Findings Tell You

Pharmacovigilance inspections are not rare events to be prepared for once. Guidance expects marketing authorisation holders to be inspected at least once every four years,[…]

Advertising and Promotion of Medicines in Greece: What EOF Actually Requires

Greece does not pre-approve your promotional material — but it does require you to file it, it bans advertising reimbursed medicines to the public, and[…]

Labelling, Readability Testing and Braille: The Requirements That Delay Launches

Labelling is the part of the dossier that companies leave until last and then discover cannot be rushed. User testing takes weeks and needs real[…]

The Sunset Clause and Renewals: Two Deadlines That Quietly End Authorisations

Most marketing authorisations are lost through inattention rather than refusal. Two provisions do the work: the renewal, which requires a positive act nine months before[…]

Transferring a Marketing Authorisation: A 30-Day Procedure with a Six-Month Tail

A marketing authorisation transfer looks like paperwork and behaves like a project. The regulatory step itself is fast — the European Medicines Agency must issue[…]

Importing Active Substances into the EU: Written Confirmations, Registration and the QP Declaration

Most finished medicines placed on the Greek and EU market rely on active substances manufactured outside the Union. The Falsified Medicines Directive closed that door[…]

PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy

The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment[…]